Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Marc Humbert - (Autor:in)
  • Gérald Simonneau - (Autor:in)
  • David Pittrow - , Institut für Klinische Pharmakologie (Autor:in)
  • Marion Delcroix - (Autor:in)
  • Joanna Pepke-Zaba - (Autor:in)
  • David Langleben - (Autor:in)
  • Lisa M Mielniczuk - (Autor:in)
  • Pilar Escribano Subias - (Autor:in)
  • Repke J Snijder - (Autor:in)
  • Joan A Barberà - (Autor:in)
  • Jens Klotsche - (Autor:in)
  • Christian Meier - (Autor:in)
  • Marius M Hoeper - (Autor:in)

Abstract

EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study in patients with pulmonary hypertension treated with riociguat. Patients were followed for 1-4 years, and the primary outcomes were adverse events (AEs) and serious AEs (SAEs), including embolic/thrombotic and hemorrhagic events. Here we report data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving a vitamin K antagonist (VKA; n = 683) or a non-vitamin K antagonist oral anticoagulant (NOAC; n = 198) at baseline. AEs and SAEs were reported in 438 patients (64.1%) and 257 patients (37.6%), respectively, in the VKA group, and in 135 patients (68.2%) and 74 patients (37.4%) in the NOAC group. Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were higher in the NOAC group, although the numbers of events were small. Further studies are required to determine the long-term effects of anticoagulation strategies in CTEPH.

Details

OriginalspracheEnglisch
Seiten (von - bis)716-721
Seitenumfang6
FachzeitschriftJournal of Heart and Lung Transplantation
Jahrgang41
Ausgabenummer6
PublikationsstatusVeröffentlicht - Juni 2022
Peer-Review-StatusJa

Externe IDs

Scopus 85126520056

Schlagworte

Schlagwörter

  • chronic thromboembolic pulmonary hypertension, drug safety, non-vitamin K antagonist oral anticoagulants, riociguat, vitamin K antagonists

Bibliotheksschlagworte